The Yin and Yang of myelodysplastic syndromes and autoimmunity: The paradox of autoimmune disorders responding to therapies specific for MDS

被引：7
|
作者：
Fozza, Claudio [1 ]
La Nasa, Giorgio [2 ]
Caocci, Giovanni [2 ]
机构：
[1] Univ Sassari, Dept Med Surg & Expt Sci, Hematol Unit, Viale San Pietro 12, I-07100 Sassari, Italy
[2] Univ Cagliari, Dept Med Sci, Hematol Unit, Cagliari, Italy
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2019年 / 142卷
关键词：
Myelodysplastic syndromes; Immunotherapy; Autoimmunity; Autoimmune manifestations; STEM-CELL TRANSPLANTATION; INTESTINAL BEHCETS-DISEASE; CORD BLOOD TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; T-CELLS; IMMUNOLOGICAL ABNORMALITIES; AZACITIDINE; 5-AZACYTIDINE; LENALIDOMIDE; EFFICACY;
D O I：
10.1016/j.critrevonc.2019.07.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The biological milieu and clinical picture of myelodysplastic syndromes (MDS) is characterised by a variety of immune mechanisms and manifestations, including an increased frequency of autoimmune disorders. The present review will try to shed some light on the potential clinical and pathogenetic implications of these immune processes in MDS by focusing on the beneficial effects exerted by some MDS-modifying therapies on autoimmune manifestations.
引用
收藏
页码：51 / 57
页数：7
相关论文
共 10 条
  • [1] Autoimmune disorders associated with myelodysplastic syndromes: clinical, prognostic and therapeutic implications
    Fozza, Claudio
    Murtas, Andrea
    Caocci, Giovanni
    La Nasa, Giorgio
    LEUKEMIA RESEARCH, 2022, 117
  • [2] Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): Cause or consequence?
    Braun, Thorsten
    Fenaux, Pierre
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (04) : 327 - 336
  • [3] Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia
    Fraison, Jean-Baptiste
    Mekinian, Arsene
    Grignano, Eric
    Kahn, Jean-Emmanuel
    Arlet, Jean-Benoit
    Decaux, Olivier
    Denis, Guillaume
    Buchdahl, Anne-Laure
    Omouri, Mohamed
    Maigne, Gwenola
    Aouba, Achille
    Leon, Nathalie
    Berthier, Sabine
    Liozon, Eric
    Park, Sophie
    Gardin, Claude
    Lortholary, Olivier
    Rossignol, Julien
    Fenaux, Pierre
    Fain, Olivier
    Braun, Thorsten
    LEUKEMIA RESEARCH, 2016, 43 : 13 - 17
  • [4] Current State and Challenges in Development of Targeted Therapies in Myelodysplastic Syndromes (MDS)
    Stanchina, Michele
    Chaudhry, Sana
    Karr, Matthew
    Taylor, Justin
    HEMATO, 2021, 2 (02): : 217 - 236
  • [5] Deciphering the prognostic significance of autoimmune disorders in myelodysplastic syndromes
    Fozza, Claudio
    ANNALS OF HEMATOLOGY, 2019, 98 (04) : 1025 - 1026
  • [6] Hyperhomocysteinemia in myelodysplastic syndromes: Specific association with autoimmunity and cardiovascular disease
    Cortelezzi, A
    Fracchiolla, NS
    Bamonti-Catena, F
    Motta, M
    Cighetti, G
    Carrabba, M
    Cavalca, V
    Maiolo, AT
    Deliliers, GL
    LEUKEMIA & LYMPHOMA, 2001, 41 (1-2) : 147 - 150
  • [7] Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions
    Bidikian, Aram
    Bewersdorf, Jan P.
    Shallis, Rory M.
    Getz, Ted M.
    Stempel, Jessica M.
    Kewan, Tariq
    Stahl, Maximilian
    Zeidan, Amer M.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (11) : 1131 - 1146
  • [8] Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database
    Wilson, Amanda B.
    Neogi, Tuhina
    Prout, Marianne
    Jick, Susan
    CANCER EPIDEMIOLOGY, 2014, 38 (05) : 544 - 549
  • [9] Response of autoimmune and inflammatory disorders in myelodysplastic syndromes to 5-azacytidine: report of two cases and literature review
    Wu, Dan-Yang
    Wang, Jing
    Zhang, Rui
    Yan, Xiao-Jing
    Gao, Ran
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (08) : 9276 - 9280
  • [10] Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS
    Kuendgen, A.
    Nomdedeu, M.
    Tuechler, H.
    Garcia-Manero, G.
    Komrokji, R. S.
    Sekeres, M. A.
    Della Porta, M. G.
    Cazzola, M.
    DeZern, A. E.
    Roboz, G. J.
    Steensma, D. P.
    Van de Loosdrecht, A. A.
    Schlenk, R. F.
    Grau, J.
    Calvo, X.
    Blum, S.
    Pereira, A.
    Valent, P.
    Costa, D.
    Giagounidis, A.
    Xicoy, B.
    Doehner, H.
    Platzbecker, U.
    Pedro, C.
    Luebbert, M.
    Oiartzabal, I
    Diez-Campelo, M.
    Cedena, M. T.
    Machherndl-Spandl, S.
    Lopez-Pavia, M.
    Baldus, C. D.
    Martinez-de-Sola, M.
    Stauder, R.
    Merchan, B.
    List, A.
    Ganster, C.
    Schroeder, T.
    Voso, M. T.
    Pfeilstoecker, M.
    Sill, H.
    Hildebrandt, B.
    Esteve, J.
    Nomdedeu, B.
    Cobo, F.
    Haas, R.
    Sole, F.
    Germing, U.
    Greenberg, P. L.
    Haase, D.
    Sanz, G.
    LEUKEMIA, 2021, 35 (03) : 835 - 849
1